HCA Healthcare (HCA)
(Delayed Data from NYSE)
$319.70 USD
+4.58 (1.45%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $319.88 +0.18 (0.06%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
HCA Healthcare (HCA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$347.59 | $397.00 | $279.00 | 10.30% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for HCA Healthcare comes to $347.59. The forecasts range from a low of $279.00 to a high of $397.00. The average price target represents an increase of 10.3% from the last closing price of $315.12.
Analyst Price Targets (22)
Broker Rating
HCA Healthcare currently has an average brokerage recommendation (ABR) of 1.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.45 a month ago based on 22 recommendations.
Of the 22 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 72.73% and 9.09% of all recommendations. A month ago, Strong Buy made up 72.73%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 14 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.45 | 1.45 | 1.45 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/29/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/29/2024 | UBS | Aj Rice | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Gary Taylor | Strong Buy | Strong Buy |
3/28/2024 | Wells Fargo Securities | Stephen Baxter | Hold | Hold |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/5/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/4/2024 | Goldman Sachs | Jamie Perse | Hold | Hold |
1/31/2024 | Raymond James | John W Ransom | Moderate Buy | Moderate Buy |
1/31/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
1/26/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
1/4/2024 | Not Identified | Not Identified | Strong Buy | Hold |
12/4/2023 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
10/26/2023 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
10/25/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.45 |
ABR (Last week) | 1.45 |
# of Recs in ABR | 22 |
Average Target Price | $347.59 |
LT Growth Rate | 10.30% |
Industry | Medical - Hospital |
Industry Rank by ABR | 14 of 252 |
Current Quarter EPS Est: | 4.91 |